GlassScriptPhysician profile
Barbara J Green
NPI 1497783997
$351,597.96
in general payments reported to CMS, 2019-2025
35 companies · $8,185 in 2025
The $8,185 reported for 2025 was more than what 88% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $69K · 2021: $65K · 2022: $88K · 2023: $30K · 2024: $21K · 2025: $8,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $7,026 · Consulting Fee: $5,585 · Travel and Lodging: $307 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,579.00 |
| Food and Beverage | $7,025.80 |
| Consulting Fee | $5,585.00 |
| Travel and Lodging | $307.44 |
| Education | $234.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $113,571.21 | 2019-2023 | Tysabri, Vumerity, Tecfidera |
| Emd Serono, INC. | $95,716.70 | 2019-2024 | Mavenclad, Mavenclad |
| Genzyme Corporation | $36,551.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $19,716.26 | 2020-2022 | |
| Celgene Corporation | $19,084.59 | 2020-2024 | Zeposia |
| Genentech USA, INC. | $18,075.71 | 2019-2024 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $12,225.45 | 2019 | |
| Vanda Pharmaceuticals INC. | $11,873.66 | 2024-2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $10,554.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $4,944.95 | 2019-2025 | |
| Greenwich Biosciences, INC. | $3,048.00 | 2021 | |
| Tg Therapeutics, INC. | $2,275.08 | 2021-2025 | |
| Banner Life Sciences, LLC | $900.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $850.00 | 2021 | |
| Amgen INC. | $383.37 | 2019-2024 | Uplizna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $283.98 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $267.48 | 2023-2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $218.59 | 2019-2024 | Ultomiris |
| Genentech, INC. | $199.44 | 2022-2025 | Ocrevus |
| Horizon Therapeutics Plc | $163.62 | 2021-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $102.80 | 2022 | |
| Lilly USA, LLC | $85.70 | 2019-2024 | Emgality |
| Otsuka America Pharmaceutical, INC. | $66.49 | 2023-2024 | Nuedexta |
| Sanofi-Aventis U.S. LLC | $59.68 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $56.21 | 2021 | |
| Avanir Pharmaceuticals, INC. | $52.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $51.69 | 2023 | Evusheld |
| Pfizer INC. | $43.53 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $43.27 | 2023-2024 | Qelbree |
| Mdd US Operations, LLC | $42.73 | 2024 | Apokyn |
| Acorda Therapeutics, INC | $32.13 | 2023 | Inbrija, Ampyra |
| Lundbeck LLC | $22.23 | 2023 | Vyepti |
| Sumitomo Pharma America, INC. | $20.32 | 2024 | Aptiom |
| Bayer Healthcare Pharmaceuticals INC. | $14.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.